Contact:Dorit Hayon, BDFoamix Pharmaceuticals Ltd.+972-8-9316233IR@foamixpharma.comUS Investor RelationsMichael RiceLifeSci Advisors, LLC646email@example.com
REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr. Dov Tamarkin, CEO, will provide a corporate overview and business update at the Rodman & Renshaw 18th Annual Global Investment Conference, taking place in New York City, New York, September 11-13, 2016. Presentation Details: Title: Rodman & Renshaw 18th Annual Global Investment ConferenceDate: Monday, September 12Time: 2:35 p.m. Eastern TimeLocation: The Lotte New York Palace Hotel, New York City About Foamix Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX103 for the treatment of rosacea and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs. In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Mylan. For more information, please visit www.foamixpharma.com.